Last reviewed · How we verify

NCT06578520

Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure

Recruiting now Phase 4 Last updated 6 August 2025
What this trial tests

Phase 4 trial testing Dapagliflozin in Heart Failure in 31 participants. Currently enrolling.

Timeline
30 July 2024
Primary endpoint
1 December 2025
31 December 2025

Quick facts

Lead sponsorFundación para la Investigación del Hospital Clínico de Valencia
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment31
Start date30 July 2024
Primary completion1 December 2025
Estimated completion31 December 2025
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Fundación para la Investigación del Hospital Clínico de Valencia

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cross-over, 2-sequence, 2-treatment, 2-period single-centre, phase IV, randomized, open label study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dapagliflozin

Trials testing the same drug.

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Fundación para la Investigación del Hospital Clínico de Valencia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06578520.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing